文献速递外周动脉疾病

孤立性股腘动脉外周血管介入术后临床失败的高风险特征

High-Risk Characteristics for Clinical Failure after Isolated Femoropopliteal Peripheral Vascular Interventions.
PubMed 文献 · Ann Vasc Surg · 2023-04-23

基于血管质量倡议数据库2016—2019年4856例因间歇性跛行或静息痛行孤立性股腘动脉外周血管介入的患者,建立并验证临床失败风险评分。1年内718例(14.8%)发生临床失败,模型区分度良好(开发集C统计量0.71,验证集0.72),标准风险、高风险和极高风险患者的预测临床失败率分别为8.9%、15.5%和33.8%。

要点

  • 年龄≤50岁、女性、胰岛素依赖型糖尿病、肌酐>2.0 mg/dL、既往同侧下肢血运重建、既往同侧小截肢、静息痛、闭塞长度≥20 cm及TASC II C/D级与临床失败相关。
  • 风险评分预测临床失败率:标准风险8.9%(占45.9%的介入),高风险15.5%(占44.2%),极高风险33.8%(占9.8%)。
  • 模型区分度良好,开发集C统计量0.71,验证集0.72。

核心结论

  • 新型风险评分对股腘动脉外周血管介入术后1年临床失败具有良好区分度,高风险和极高风险患者可能从包括紫杉醇涂层器械在内的替代策略中获益。
  • 美国食品药品监督管理局建议将紫杉醇涂层器械的使用限制于「再狭窄风险特别高的患者」。

研究设计与样本

  • 基于血管质量倡议数据库2016—2019年因间歇性跛行或静息痛行孤立性股腘动脉外周血管介入的患者。
  • 排除接受紫杉醇涂层器械介入、杂交手术、1年内死亡或随访数据缺失的患者。
  • 数据随机分为2/3用于开发、1/3用于验证,采用简约多变量分层逻辑回归建立临床失败模型,并基于β系数创建风险评分。
  • 主要终点为1年临床失败,定义为再狭窄>50%、通畅性丧失、再次介入或大截肢。

主要发现

  • 4856例接受治疗的患者中,718例(14.8%)在1年内发生临床失败。
  • 临床失败与年龄≤50岁、女性(48.1% vs. 39.5%)、胰岛素依赖型糖尿病(29.9% vs. 23.1%)、肌酐>2.0 mg/dL(9.9% vs. 5.7%)、既往同侧下肢血运重建(48.5% vs. 38.5%)、既往同侧小截肢(5.3% vs. 1.7%)、静息痛 vs. 间歇性跛行(30.8% vs. 18.7%)、闭塞长度≥20 cm(18.8% vs. 15.0%)及TASC II C或D级(40.4% vs. 28.0%)相关,所有P≤0.01。
  • 模型拟合良好且区分度良好,开发集C统计量0.71,验证集0.72。
  • 预测临床失败率:标准风险8.9%(占45.9%的介入),高风险15.5%(占44.2%的介入),极高风险33.8%(占9.8%的介入)。

关键数值与推荐

  • 风险评分预测临床失败率:标准风险8.9%(占45.9%的介入),高风险15.5%(占44.2%的介入),极高风险33.8%(占9.8%的介入)。
  • 模型区分度:开发集C统计量0.71,验证集0.72。
  • 美国食品药品监督管理局建议将紫杉醇涂层器械的使用限制于「再狭窄风险特别高的患者」。

临床怎么用

  • 新型风险评分可用于识别股腘动脉外周血管介入术后1年临床失败高风险患者。
  • 高风险和极高风险患者可能从包括紫杉醇涂层器械在内的替代策略中获益(作者结论)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent studies suggesting increased late mortality with paclitaxel-coated devices (PCDs) in femoropopliteal peripheral vascular interventions (PVIs) prompted the US Food and Drug Administration to recommend limiting the use of PCDs to "patients at particularly high risk for restenosis". This study's aim is to characterize patients at high risk for restenosis and develop a risk score to guide clinicians in selecting patients for treatment with PCDs. METHODS: Patients who underwent isolated femoropopliteal PVI for claudication or rest pain from 2016-2019 in the Vascular Quality Initiative were included. Patients who received intervention with a PCD, hybrid procedures, died within 1 year, or had missing follow-up data were excluded. The primary end point was clinical failure at 1 year defined as > 50% restenosis, loss of patency, reintervention, or major amputation. Data were split randomly into 2/3 for development and 1/3 for validation. A parsimonious multivariable hierarchical logistic regression for clinical failure was developed and a risk score was created using beta-coefficients. The risk score was applied to the validation dataset and tested for goodness-of-fit and discrimination. RESULTS: Among 4,856 treated patients, 718 (14.8%) experienced clinical failure within 1 year. Clinical failure was associated with age ≤ 50 years, female sex (48.1% vs. 39.5%), insulin-dependent diabetes (29.9% vs. 23.1%), creatinine > 2.0 mg/dL (9.9% vs. 5.7%), prior ipsilateral lower extremity revascularization (48.5% vs. 38.5%), prior ipsilateral minor amputation (5.3% vs. 1.7%), rest pain versus claudication (30.8% vs. 18.7%), occlusion length ≥ 20 cm (18.8% vs. 15.0%), and Trans-Atlantic Inter-Society Consensus II Classification C or D (40.4% vs. 28.0%), all P ≤ 0.01. Risk score development was performed using a multivariable regression. The model demonstrated good fit and discrimination (C-statistic 0.71 in development and 0.72 in validation dataset). Predicted clinical failure was 8.9% for standard-risk (45.9% of interventions), 15.5% for high-risk (44.2% of interventions), and 33.8% for very high-risk patients (9.8% of interventions). CONCLUSIONS: A novel risk score was created with good discrimination for identifying patients at high risk for clinical failure at 1 year after femoropopliteal PVI for claudication and rest pain. Patients at high risk and very high risk for clinical failure may benefit from alternative strategies including PCDs.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kim TI, Schneider PA, Iannuzzi J, et al. High-Risk Characteristics for Clinical Failure after Isolated Femoropopliteal Peripheral Vascular Interventions. Ann Vasc Surg. 2023. PMID: 37088359. doi:10.1016/j.avsg.2023.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。